Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Cyclic GMP
100%
Hypertension
100%
Novel Peptide
100%
Peptide Drugs
100%
Resistant Hypertension
83%
Aldosterone
66%
Blood Pressure Lowering
50%
Specific Aims
50%
African American
50%
Spontaneously Hypertensive Rats
33%
Natriuresis
33%
Positive Allosteric Modulator
33%
Blood Pressure
33%
Cardiorenal
33%
Once-daily
16%
High Risk
16%
Clinical Trials Unit
16%
Human Hypertension
16%
Synergism
16%
Blood Protection
16%
Low Blood Pressure
16%
Approved Drugs
16%
Primary Cells
16%
Natriuretic Peptides
16%
Subcutaneous Injection
16%
Severe Hypertension
16%
Clinical Science
16%
Cardiac Hormones
16%
Protective Behavior
16%
Mayo Clinic
16%
Sodium Excretion
16%
Translational Science
16%
Blood Pressure Regulation
16%
Particulate Guanylyl Cyclase
16%
Genetic Variation
16%
Neprilysin
16%
Best-in-class
16%
Human Studies
16%
Metabolic Syndrome
16%
Well Tolerated
16%
Vasodilation
16%
Antifibrotic
16%
Endogenous Ligand
16%
Ethnic Population
16%
Small Molecules
16%
Guanylyl Cyclase Receptor
16%
Pharmacology, Toxicology and Pharmaceutical Science
Peptide
100%
Hypertension
100%
Cyclic GMP
100%
Resistant Hypertension
83%
Aldosterone
66%
Positive Allosteric Modulator
33%
Spontaneously Hypertensive Rat
33%
Anti-Inflammatory Drug
16%
Sacubitril Plus Valsartan
16%
Receptor
16%
Synergism
16%
Sodium
16%
Hypotension
16%
Clinical Research
16%
Metabolic Syndrome X
16%
Subcutaneous Injection
16%
Human Study
16%
Membrane Metalloendopeptidase
16%
Guanylate Cyclase
16%
Natriuretic Factor
16%